Skip to main content

Metformin / Pioglitazone Dosage

Medically reviewed by Drugs.com. Last updated on Jul 31, 2023.

Applies to the following strengths: 500 mg-15 mg; 850 mg-15 mg; 1000 mg-30 mg; 1000 mg-15 mg

Usual Adult Dose for Diabetes Type 2

Individualize dose based on safety, efficacy, and prior therapy


Immediate-release (IR):
Initial dose: 15 mg/500 mg IR orally twice a day or 15 mg/850 mg IR orally once a day
Maintenance dose: Gradually titrate dose based on safety and efficacy
Maximum dose: Pioglitazone 45 mg/Metformin 2550 mg per day

Extended-release (XR):
Initial dose: 15 mg/1000 mg XR or 30 mg/1000 mg XR orally once a day
Maintenance dose: Gradually titrate dose based on safety and efficacy
Maximum dose: Pioglitazone 45 mg/Metformin 2000 mg per day

Comments:

Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate.

Renal Dose Adjustments



IODINATED CONTRAST PROCEDURE:

Liver Dose Adjustments

Avoid use in patients with clinical or laboratory evidence of hepatic disease

Liver function tests (ALT, AST, alkaline phosphatase, and total bilirubin) should be obtained prior to therapy

Dose Adjustments

Elderly: Renal function should be assessed more frequently in elderly patients.

New York Heart Association (NYHA) Class I or Class II Heart Failure:


IODINATED CONTRAST PROCEDURES:

Concomitant use with Strong CYP450 2C8 Inhibitors:

Hypoglycemia:

Therapeutic drug monitoring/range: Steady-state plasma concentrations of metformin are achieved within 24 to 48 hours and are generally less than 1 mcg/mL. Metformin levels greater than 5 mcg/mL have been implicated as the cause of lactic acidosis.

Precautions

US BOXED WARNING(S): Congestive Heart Failure and Lactic Acidosis:

LACTIC ACIDOSIS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Other Comments

Administration advice:


General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.